Mefamol
Anti-Inflammatory ,Analgesic,Antipyretic
  • The active substance in Mefamol® Oral suspension  is Mefenamic Acid that is a non-steroidal anti-inflammatory drug (NSAIDs) that exhibits anti-inflammatory, analgesic and antipyretic activities. 
     

Each 5ml contains :

  • Mefenamic Acid     50 mg

Mefamol® Oral suspension is indicated for treatment of the following:

  • For the relief of mild to moderate pain including muscular or traumatic origin, headache, dental pain and post-operative pain.
  • For the relief of pain associated with rheumatoid  arthritis (including Still’s disease) and osteoarthritis.
  • Mefamol® Oral suspension also used as an antipyretic.

Mefamol® Oral suspension is contraindicated in the following cases:

  • Patients with hypersensitivity to Mefenamic Acid  or patients in whom aspirin or other  Non-steroidal anti-inflammatory drugs precipitate symptoms of bronchospasm, allergic rhinitis or  urticaria.
  • Patients with inflammatory bowel disease, and peptic ulceration.
  • Patients with renal or hepatic impairment.
  • Patients with Porphyria. 
  • Mefenamic Acid may enhance of the effects of oral anticoagulants and increase plasma concentrations of lithium, methotrexate, and cardiac glycosides.
  • It may interact with hydantoins.
  • Diarrhea and rashes.
  • Drowsiness and dizziness. 
  • Effects on the blood including thrombocytopenia, occasionally haemolytic anaemia, and rarely aplastic anaemia.

Overdose:

  • Mefenamic acid overdose has been associated with CNS toxicity, especially with convulsions, which if prolonged or recurrent require treatment. Coma has also been reported.

¤ Mefamol® Oral suspension is administrated after meals.

  • Children (6 monthes-2 years): One teaspoonful (5ml);
  • Children (2 years-5 years): Two teaspoonful (10ml);
  • Children (5 years-9 years): Three teaspoonful (15ml);
  • Children (9 years-12 years): Four teaspoonful (20ml);To be taken three times a day or as directed.

- It is recommended that it should not be given for longer than 7 days to children unless they are receiving mefenamic acid for juvenile chronic arthritis (Still’s disease).

  • Apart from Still’s disease, therapy should not be continued for longer than 7 days in children. 
  • Treatment should be discontinued if diarrhea and rashes occur.
  • It should be taken with precaution in pregnancy and during breast feeding.
  • Bottle of 60 ml Oral Suspension .
  • Store in a dry place at temperature not exceeding 25°C.
  • Protect from direct sunlight.